Adenylate kinase activity in the cerebrospinal fluid of children with tuberculous meningitis and its relationship to neurological outcome

Simple item page
dc.contributor.authorCarlini S.M.
dc.contributor.authorBeyers N.
dc.contributor.authorSchoeman J.F.
dc.contributor.authorNel E.D.
dc.contributor.authorTruter E.J.
dc.contributor.authorDonald P.R.
dc.date.accessioned2011-05-15T16:17:54Z
dc.date.available2011-05-15T16:17:54Z
dc.date.issued1997
dc.description.abstractCerebrospinal fluid (CSF) adenylate kinase activity was determined in 88 children (mean age 32.6 months) at stage II (n = 40) and stage III (n = 48) tuberculous meningitis (TBM) at, or shortly after, the initiation of treatment, and at weekly intervals thereafter for the first month of treatment, and in 60 children (mean age 40 months) investigated for, but later considered not to have meningitis. CSF adenylate kinase activity in this latter group ranged from 0 to 1.27 u/l (mean 0.59 u/l). Mean CSF adenylate kinase activity during the first week of therapy in children at stage II TBM (2.95 u/l; range 0-9.22 u/l) differed significantly (p = 0.03) from that in children at stage III TBM (5.62 u/l; range 0-18.93 u/l). CSF adenylate kinase activity did not differ between children at stage II and stage III TBM during any of the 3 subsequent weeks. CSF adenylate kinase activity was not related to CSF cell count, total protein or glucose concentration or intracranial pressure at any point during the first month of treatment, but was related to CSF lactate during the first week of therapy (p = 0.001). Consecutive determinations of CSF adenylate kinase activity were available in 34 children. Although CSF adenylate kinase activity tended to increase or decrease in keeping with changes in clinical condition this was not always the case. The close relationship of CSF adenylate kinase activity and lactate concentrations suggests that adenylate kinase activity reflects hypoxic cerebral metabolism and it was unusual for children with increased CSF adenylate kinase activity at the time of diagnosis to be clinically normal on completion of 6 months of antituberculosis treatment. Any treatment modality which significantly reduced CSF adenylate kinase activity in children early in the course of TBM would probably be of clinical benefit to the patients.
dc.description.versionArticle
dc.identifier.citationScandinavian Journal of Infectious Diseases
dc.identifier.citation29
dc.identifier.citation3
dc.identifier.issn00365548
dc.identifier.urihttp://hdl.handle.net/10019.1/14425
dc.subjectadenylate kinase
dc.subjectethionamide
dc.subjectisoniazid
dc.subjectlactic acid
dc.subjectpyrazinamide
dc.subjectrifampicin
dc.subjectadolescent
dc.subjectarticle
dc.subjectcerebrospinal fluid
dc.subjectcerebrospinal fluid level
dc.subjectenzyme activity
dc.subjecthearing
dc.subjecthuman
dc.subjectinfant
dc.subjectintelligence
dc.subjectmajor clinical study
dc.subjectmotor performance
dc.subjecttreatment outcome
dc.subjecttuberculous meningitis
dc.subjectvision
dc.subjectAdenylate Kinase
dc.subjectAdolescent
dc.subjectAntitubercular Agents
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectDrug Therapy, Combination
dc.subjectHumans
dc.subjectInfant
dc.subjectLactic Acid
dc.subjectNervous System Diseases
dc.subjectTreatment Outcome
dc.subjectTuberculosis, Meningeal
dc.titleAdenylate kinase activity in the cerebrospinal fluid of children with tuberculous meningitis and its relationship to neurological outcome
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Tygerberg Hospital Publications